Aleksei Dmitrievich Kravchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aleksei Dmitrievich Kravchenko has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Natalia Valeryevna Pyatigorskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Natal'YA Sergeevna Nikolenko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Alexander Kyrychenko
V. N. Karazin Kharkiv National University
1 shared publication - Ekaterina Igorevna Nesterkina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Galina Eduardovna Brkich
I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)
1 shared publication - Larysa Yevsieieva
V. N. Karazin Kharkiv National University
1 shared publication
Latest Publications
- Open Access
- 31 August 2022
- Published byΒ Center of Pharmaceutical Analytics LtdΒ inΒ Drug development & registration
- Vol.Β 11 Β (3) , 195-201
Caco-2 Intestinal Permeability Study of Phenyltetrahydroquinolinedione Derivative β TRPAβ Antagonist
Introduction. This work is devoted to the intestinal permeability study of 7-(2-chlorophenyl)-4-(4-methyl-1,3-thiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione β innovative biologically active substance with TRPA1 antagonist activity. The phenyltetrahydroquinolinedione derivative is a promising analgesic and anti-inflammatory drug. To develop a dosage form of this new substance, it is necessary to study the mechanism and degree of its absorption.Aim. The aim of this work was to investigate the intestinal permeability of the phenyltetrahydroquinolinedione derivative using Caco-2 cell model and to compare experimental results with the in silico obtained values of the octanol/water partition coefficients.Materials and methods. The study of permeability was carried out from the apical membrane to the basolateral (A-B) and in the opposite direction (B-A). Ranitidine (low permeability), propranolol (high permeability) and rhodamine 123 (P-glycoprotein substrate) were used as control compounds. The concentration of the test compound was determined by UHPLC-MS/MS system consisting of a liquid chromatograph and a tandem mass spectrometer with a triple quadrupole and an electrospray ion source. The logP was calculated using the following resources: ChemDraw Professional 16.0, Molinspiration, ALOGPS 2.1.Results and discussion. The values of the apparent permeability (Papp) and efflux ratios of the test and control compounds were obtained. According to the results of the study, the following conclusions were made: the test compound has high permeability both in the forward direction from the apical to the basolateral cell membrane, and in the opposite direction (Papp > 10 Γ 10-6 cm/s). P-glycoprotein-mediated efflux activity was not observed (the efflux ratio was less than 2 units). The permeability did not depend on the test compound input concentration. The obtained experimental Papp values were correlated with the in silico obtained values of partition coefficients. The best correlation was obtained for milogP (Molinspiration) and ClogP (ChemDraw).Conclusion. Thus, the in vitro and in silico obtained data indicate that passive diffusion is the main mechanism of absorption of the test compound in the gastrointestinal tract.
- 31 August 2022
- Published byΒ Center of Pharmaceutical Analytics LtdΒ inΒ Drug development & registration
- Vol.Β 11 Β (3) , 195-201
Open AccessCaco-2 Intestinal Permeability Study of Phenyltetrahydroquinolinedione Derivative β TRPAβ Antagonist
Introduction. This work is devoted to the intestinal permeability study of 7-(2-chlorophenyl)-4-(4-methyl-1,3-thiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione β innovative biologically active substance with TRPA1 antagonist activity. The phenyltetrahydroquinolinedione derivative is a promising analgesic and anti-inflammatory drug. To develop a dosage form of this new substance, it is necessary to study the mechanism and degree of its absorption.Aim. The aim of this work was to investigate the intestinal permeability of the phenyltetrahydroquinolinedione derivative using Caco-2 cell model and to compare experimental results with the in silico obtained values of the octanol/water partition coefficients.Materials and methods. The study of permeability was carried out from the apical membrane to the basolateral (A-B) and in the opposite direction (B-A). Ranitidine (low permeability), propranolol (high permeability) and rhodamine 123 (P-glycoprotein substrate) were used as control compounds. The concentration of the test compound was determined by UHPLC-MS/MS system consisting of a liquid chromatograph and a tandem mass spectrometer with a triple quadrupole and an electrospray ion source. The logP was calculated using the following resources: ChemDraw Professional 16.0, Molinspiration, ALOGPS 2.1.Results and discussion. The values of the apparent permeability (Papp) and efflux ratios of the test and control compounds were obtained. According to the results of the study, the following conclusions were made: the test compound has high permeability both in the forward direction from the apical to the basolateral cell membrane, and in the opposite direction (Papp > 10 Γ 10-6 cm/s). P-glycoprotein-mediated efflux activity was not observed (the efflux ratio was less than 2 units). The permeability did not depend on the test compound input concentration. The obtained experimental Papp values were correlated with the in silico obtained values of partition coefficients. The best correlation was obtained for milogP (Molinspiration) and ClogP (ChemDraw).Conclusion. Thus, the in vitro and in silico obtained data indicate that passive diffusion is the main mechanism of absorption of the test compound in the gastrointestinal tract.
- Open Access
- 19 July 2022
- Published byΒ Belgorod National Research UniversityΒ inΒ Research Results in Pharmacology
- Vol.Β 8 Β (3) , 19-29
Transient receptor potential Ankyrin 1: structure, function and ligands
Introduction: Transient receptor potential ankyrin 1 (TRPA1) is a protein expressed in many living organisms. During the study of TRPA1, its unique biological role as a universal and polymodal sensor of various altering agents was found. The aim of this study is to search and generalize information about structural features and molecular determinants, mechanisms of activation, action and modulation of TRPA1 as a universal pain and inflammation sensor, as well as the nature of activators and antagonists of this target and their therapeutic potential. Materials and methods: This article presents an overview of the results of scientific research of TRPA1, its modulators, as well as an overview of their pharmacological potential over the period from the discovery of these channels to the present, with an emphasis on the last decade. Results and discussion: The main collected data on expression, structural features and molecular determinants, mechaΒnisms of activation and action of TRPA1 indicate its role as a universal and labile element of the primary response of the body to adverse exogenous and endogenous factors. Regardless of the nature of the stimulus, hyperstimulation of TRPA1 channels can lead to such phenomena as pain, inflammation, itching, edema and other manifestations of alteration, and therefore TRPA1 blockade can be used in the treatment of various diseases accompanied by these pathological conditions. Currently, TRPA1 antagonists are being actively searched for and studied, as evidenced by a high patent activity over the past 14 years; however, the molecular mechanisms of action and pharmacological properties of TRPA1 blockers remain understudied. Conclusion: Acquire of new information about TRPA1 will help in the development of its modulators, which can beΒcome promising analgesics, anti-inflammatory drugs, bronchodilators, and agents for the treatment of cardiovascular diseases of new generations.
- 19 July 2022
- Published byΒ Belgorod National Research UniversityΒ inΒ Research Results in Pharmacology
- Vol.Β 8 Β (3) , 19-29
Open AccessTransient receptor potential Ankyrin 1: structure, function and ligands
Introduction: Transient receptor potential ankyrin 1 (TRPA1) is a protein expressed in many living organisms. During the study of TRPA1, its unique biological role as a universal and polymodal sensor of various altering agents was found. The aim of this study is to search and generalize information about structural features and molecular determinants, mechanisms of activation, action and modulation of TRPA1 as a universal pain and inflammation sensor, as well as the nature of activators and antagonists of this target and their therapeutic potential. Materials and methods: This article presents an overview of the results of scientific research of TRPA1, its modulators, as well as an overview of their pharmacological potential over the period from the discovery of these channels to the present, with an emphasis on the last decade. Results and discussion: The main collected data on expression, structural features and molecular determinants, mechaΒnisms of activation and action of TRPA1 indicate its role as a universal and labile element of the primary response of the body to adverse exogenous and endogenous factors. Regardless of the nature of the stimulus, hyperstimulation of TRPA1 channels can lead to such phenomena as pain, inflammation, itching, edema and other manifestations of alteration, and therefore TRPA1 blockade can be used in the treatment of various diseases accompanied by these pathological conditions. Currently, TRPA1 antagonists are being actively searched for and studied, as evidenced by a high patent activity over the past 14 years; however, the molecular mechanisms of action and pharmacological properties of TRPA1 blockers remain understudied. Conclusion: Acquire of new information about TRPA1 will help in the development of its modulators, which can beΒcome promising analgesics, anti-inflammatory drugs, bronchodilators, and agents for the treatment of cardiovascular diseases of new generations.
- 30 April 2022
- Published byΒ Folium Publishing CompanyΒ inΒ Π₯ΠΈΠΌΠΈΠΊΠΎ-ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π»
- Vol.Β 56 Β (4) , 48-52
ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° Ρ TRPA1-Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ
ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π½ΠΎΠ²Π°Ρ Π°ΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΡ Ρ TRPA1-Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ (ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ΅ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π°) ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ Π±Π΅Π»ΡΠΉ ΠΈΠ»ΠΈ ΠΏΠΎΡΡΠΈ Π±Π΅Π»ΡΠΉ ΠΌΠ΅Π»ΠΊΠΎΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π½Π΅Π³ΠΈΠ³ΡΠΎΡΠΊΠΎΠΏΠΈΡΠ½ΡΠΉ ΠΏΠΎΡΠΎΡΠΎΠΊ, ΡΠΎΡΡΠΎΡΡΠΈΠΉ ΠΈΠ· ΡΠ°ΡΡΠΈΡ ΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΡ Ρ Π±ΠΎΠ»ΡΡΠΎΠΉ ΠΏΠ»ΠΎΡΠ°Π΄ΡΡ ΠΏΠΎΠ²Π΅ΡΡ Π½ΠΎΡΡΠΈ: D90 ΠΈ span ΡΠΎΡΡΠ°Π²Π»ΡΡΡ 22,2 ΠΌΠΊΠΌ ΠΈ 1,9 Π΅Π΄ΠΈΠ½ΠΈΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. Π‘ΡΠ±ΡΡΠ°Π½ΡΠΈΡ ΡΠΌΠ΅ΡΠ΅Π½Π½ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠ° Π² ΡΡΠ°Π½ΠΎΠ»Π΅ 96 % ΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠ° Π² Π²ΠΎΠ΄Π΅ ΠΈ Π½-Π³Π΅ΠΊΡΠ°Π½Π΅, ΠΏΠ»Π°Π²ΠΈΡΡΡ Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡ ΠΎΡ 203,5 Π΄ΠΎ 208,3 Β°C Ρ ΡΠ°Π·Π»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΠΌ, ΡΠ΅ΡΡΠ΅Ρ 0,11 % ΠΌΠ°ΡΡΡ ΠΏΡΠΈ Π²ΡΡΡΡΠΈΠ²Π°Π½ΠΈΠΈ, ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ 0,096 % Π²ΠΎΠ΄Ρ ΠΈ 99,3 % Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ²Π°Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° Π½Π°ΠΊΠ»Π°Π΄ΡΠ²Π°ΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΠ΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ Π½Π° ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΡ ΠΈ ΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°ΡΡ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡ ΠΊ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Π°ΠΌ ΠΊ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΠΎΡΠΌ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΠΏΡΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΎΠ΅ΠΊΡΠ° ΡΠΏΠ΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π½Π° ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΡ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΡ.
- 30 April 2022
- Published byΒ Folium Publishing CompanyΒ inΒ Π₯ΠΈΠΌΠΈΠΊΠΎ-ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π»
- Vol.Β 56 Β (4) , 48-52
ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° Ρ TRPA1-Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ
ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π½ΠΎΠ²Π°Ρ Π°ΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΡ Ρ TRPA1-Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ (ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ΅ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π°) ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ Π±Π΅Π»ΡΠΉ ΠΈΠ»ΠΈ ΠΏΠΎΡΡΠΈ Π±Π΅Π»ΡΠΉ ΠΌΠ΅Π»ΠΊΠΎΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π½Π΅Π³ΠΈΠ³ΡΠΎΡΠΊΠΎΠΏΠΈΡΠ½ΡΠΉ ΠΏΠΎΡΠΎΡΠΎΠΊ, ΡΠΎΡΡΠΎΡΡΠΈΠΉ ΠΈΠ· ΡΠ°ΡΡΠΈΡ ΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΡ Ρ Π±ΠΎΠ»ΡΡΠΎΠΉ ΠΏΠ»ΠΎΡΠ°Π΄ΡΡ ΠΏΠΎΠ²Π΅ΡΡ Π½ΠΎΡΡΠΈ: D90 ΠΈ span ΡΠΎΡΡΠ°Π²Π»ΡΡΡ 22,2 ΠΌΠΊΠΌ ΠΈ 1,9 Π΅Π΄ΠΈΠ½ΠΈΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. Π‘ΡΠ±ΡΡΠ°Π½ΡΠΈΡ ΡΠΌΠ΅ΡΠ΅Π½Π½ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠ° Π² ΡΡΠ°Π½ΠΎΠ»Π΅ 96 % ΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠ° Π² Π²ΠΎΠ΄Π΅ ΠΈ Π½-Π³Π΅ΠΊΡΠ°Π½Π΅, ΠΏΠ»Π°Π²ΠΈΡΡΡ Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡ ΠΎΡ 203,5 Π΄ΠΎ 208,3 Β°C Ρ ΡΠ°Π·Π»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΠΌ, ΡΠ΅ΡΡΠ΅Ρ 0,11 % ΠΌΠ°ΡΡΡ ΠΏΡΠΈ Π²ΡΡΡΡΠΈΠ²Π°Π½ΠΈΠΈ, ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ 0,096 % Π²ΠΎΠ΄Ρ ΠΈ 99,3 % Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ²Π°Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° Π½Π°ΠΊΠ»Π°Π΄ΡΠ²Π°ΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΠ΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ Π½Π° ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΡ ΠΈ ΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°ΡΡ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡ ΠΊ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Π°ΠΌ ΠΊ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΠΎΡΠΌ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΠΏΡΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΎΠ΅ΠΊΡΠ° ΡΠΏΠ΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π½Π° ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΡ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΡ.
- Open Access
- 30 March 2022
- Published byΒ Belgorod National Research UniversityΒ inΒ Research Results in Pharmacology
- Vol.Β 8 Β (1) , 1-11
Synthesis, molecular docking, ADMET study and in vitro pharmacological research of 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione as a promising non-opioid analgesic drug
Introduction: The discovery of novel drugs that can block the transmission of pain signals for treating the pain of various etiologies is an urgent topic in pharmaceutics. The aim of this paper is to synthesize and to investigate in vitro and in silico characteristics of a promising novel compound: 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione (HSV-DKH-0450). Materials and methods: The specific activity and the inhibitory mechanism of HSV-DKH-0450 were studied using the HEK293 culture cells expressing the IPTG-induced TRPA1 ion channels. Cardiotoxicity was determined by estimating the binding of HSV-DKH-0450 to the hERG channel. Inhibition of human liver cytochromes was determined by the effect on the activity of cytochromes 1A2, 2C9, 2D6, 2C8, and 3A4. Cellular toxicity was assessed by the effect on the viability of human hepatocytes. ADMET properties were evaluated using admetSAR and SwissADME web-based tools. Molecular docking was carried out using AutoDock Vina tools to predict the binding affinity of all HSV-DKH-0450 stereoisomers toward the TRPA1 and TRPV1 receptors. Results and discussion: In silico predictions of ADMET properties of HSV-DKH-0450 showed that it has optimal pharmaceutical profiles. A series of in vitro pharmacological studies revealed that HSV-DKH-0450 is a promising antagonist of the TRPA1 ion channel with the IC50 of 91.3 nM. The molecular docking of HSV-DKH-0450 stereoisomers against the TRPA1 and TRPV1 receptors demonstrates that they all are characterized by an approximately similar high binding affinity. Conclusion: The obtained data for substance HSV-DKH-0450 look promising for its further development as a potential therapeutic agent for pain relief.
- 30 March 2022
- Published byΒ Belgorod National Research UniversityΒ inΒ Research Results in Pharmacology
- Vol.Β 8 Β (1) , 1-11
Open AccessSynthesis, molecular docking, ADMET study and in vitro pharmacological research of 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione as a promising non-opioid analgesic drug
Introduction: The discovery of novel drugs that can block the transmission of pain signals for treating the pain of various etiologies is an urgent topic in pharmaceutics. The aim of this paper is to synthesize and to investigate in vitro and in silico characteristics of a promising novel compound: 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione (HSV-DKH-0450). Materials and methods: The specific activity and the inhibitory mechanism of HSV-DKH-0450 were studied using the HEK293 culture cells expressing the IPTG-induced TRPA1 ion channels. Cardiotoxicity was determined by estimating the binding of HSV-DKH-0450 to the hERG channel. Inhibition of human liver cytochromes was determined by the effect on the activity of cytochromes 1A2, 2C9, 2D6, 2C8, and 3A4. Cellular toxicity was assessed by the effect on the viability of human hepatocytes. ADMET properties were evaluated using admetSAR and SwissADME web-based tools. Molecular docking was carried out using AutoDock Vina tools to predict the binding affinity of all HSV-DKH-0450 stereoisomers toward the TRPA1 and TRPV1 receptors. Results and discussion: In silico predictions of ADMET properties of HSV-DKH-0450 showed that it has optimal pharmaceutical profiles. A series of in vitro pharmacological studies revealed that HSV-DKH-0450 is a promising antagonist of the TRPA1 ion channel with the IC50 of 91.3 nM. The molecular docking of HSV-DKH-0450 stereoisomers against the TRPA1 and TRPV1 receptors demonstrates that they all are characterized by an approximately similar high binding affinity. Conclusion: The obtained data for substance HSV-DKH-0450 look promising for its further development as a potential therapeutic agent for pain relief.
- 1 January 2022
- Published byΒ Russian Vrach, Publishing House Ltd.Β inΒ Farmaciya (Pharmacy)
- Vol.Β 71 Β (6) , 27-33
Polymorph screening and study of the structure of crystalline forms of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity
ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. 7-(2-Ρ Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»)-4-(4-ΠΌΠ΅ΡΠΈΠ»-1,3-ΡΠΈΠ°Π·ΠΎΠ»-5-ΠΈΠ»)-4,6,7,8-ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½-2,5(1Π,3Π)-Π΄ΠΈΠΎΠ½ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½ΠΎΠ²ΡΠΌ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΠΌ Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΎΠΌ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² TRPA1, ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ ΡΡΠ°ΡΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΡΠ΅Π΄ΡΡΠ²ΠΎΠΌ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΡ. ΠΠ»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π΅Π³ΠΎ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ, ΡΠΏΠΎΡΠΎΠ±Π½ΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° Π³ΠΎΡΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΄ΡΠΊΡΠ°. Π ΡΠ°ΠΊΠΈΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½Π°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ»ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° ΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π΄ΠΈΡΡΠ°ΠΊΡΠΈΠΎΠ½Π½ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΡΠΎΡΠΊΠΎΠ²Π°Ρ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠ°Ρ Π΄ΠΈΡΡΠ°ΠΊΡΠΈΡ Π±ΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° Π½Π° Π΄ΠΈΡΡΠ°ΠΊΡΠΎΠΌΠ΅ΡΡΠ΅ Bruker D8 Discover, ΠΎΠ±ΠΎΡΡΠ΄ΠΎΠ²Π°Π½Π½ΠΎΠΌ Π½ΠΈΠΊΠ΅Π»Π΅Π²ΡΠΌ ΡΠΈΠ»ΡΡΡΠΎΠΌ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½Π½ΠΎ-ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π΄Π΅ΡΠ΅ΠΊΡΠΎΡΠΎΠΌ. Π Π°ΡΡΠ΅ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ½ΡΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΠΉ DIFFRAC.SUITE EVA ΠΈ TOPAS 4.2. Π‘ΡΠ΅ΠΌΠΊΠ° ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»Π°ΡΡ Π² Π³Π΅ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΡΡΠ³Π³Π°-ΠΡΠ΅Π½ΡΠ°Π½ΠΎ, Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΠΎΡΡΠ°ΠΆΠ΅Π½ΠΈΡ. ΠΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»Π»Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ Π±ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ ΠΏΡΠΈ ΠΏΠ΅ΡΠ΅ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΠΈ ΠΈΡ ΡΠΌΠ΅ΡΠ΅ΠΉ. Π Π΅Π½ΡΠ³Π΅Π½ΠΎΡΡΡΡΠΊΡΡΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π±ΡΠ» Π²ΡΠΏΠΎΠ»Π½Π΅Π½ Π½Π° ΠΌΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΌ Π΄ΠΈΡΡΠ°ΠΊΡΠΎΠΌΠ΅ΡΡΠ΅ Xcalibur-3. ΠΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»ΡΠ½ΡΠ΅ ΡΡΡΡΠΊΡΡΡΡ ΡΠ°ΡΡΠΈΡΡΠΎΠ²Π°Π½Ρ ΠΏΡΡΠΌΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ SHELXTL. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎΡΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΉ Π΄ΠΈΡΡΠ°ΠΊΡΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°Π· Π² Π½Π°ΡΠΈΠ²Π½ΠΎΠΌ ΠΎΠ±ΡΠ°Π·ΡΠ΅ ΠΠ€Π‘, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΎΠ½ΠΈ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°ΡΡ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΡ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ Π±ΡΠ»ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»Π»ΠΎΠ², ΠΏΡΠΈΠ³ΠΎΠ΄Π½ΡΡ Π΄Π»Ρ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΡΡΡΡΠΊΡΡΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΡΠ΅Π½ΠΊΠ° ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² Π½Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π»Π° ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΎΠ². ΠΡΠ»ΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΈΠ· ΡΡΠ°Π½ΠΎΠ»Π° ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΠ·ΡΠ΅ΡΡΡ ΡΠΎΠΌΠ±ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ I, Π° ΠΈΠ· ΠΌΠ΅ΡΠ°Π½ΠΎΠ»Π°, ΠΈΠ·ΠΎΠΏΡΠΎΠΏΠ°Π½ΠΎΠ»Π°, Π°ΡΠ΅ΡΠΎΠ½Π°, ΡΠΌΠ΅ΡΠ΅ΠΉ Π°ΡΠ΅ΡΠΎΠ½/Π°ΡΠ΅ΡΠΎΠ½ΠΈΡΡΠΈΠ» ΠΈΠ»ΠΈ Π’ΠΠ€/Π°ΡΠ΅ΡΠΎΠ½ΠΈΡΡΠΈΠ» - ΡΡΠΈΠΊΠ»ΠΈΠ½Π½Π°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ II. ΠΡΠ»ΠΈ ΠΎΠΏΠΈΡΠ°Π½Ρ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΌ ΡΡΡΠΎΠ΅Π½ΠΈΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΎΠ² ΠΈ ΠΈΡ ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠΈ Π² ΠΊΡΠΈΡΡΠ°Π»Π»Π°Ρ . ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΈ ΠΎΡ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΡ ΠΠ€Π‘ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΎΡΠ΅Π½Π΅Π½Ρ Ρ ΡΠ΅Π»ΡΡ Π²ΡΠ±ΠΎΡΠ° ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΎΠΉ ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π΄Π»Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ Π½Π° Π΅Π΅...
- 1 January 2022
- Published byΒ Russian Vrach, Publishing House Ltd.Β inΒ Farmaciya (Pharmacy)
- Vol.Β 71 Β (6) , 27-33
Polymorph screening and study of the structure of crystalline forms of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity
ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. 7-(2-Ρ Π»ΠΎΡΠΎΡΠ΅Π½ΠΈΠ»)-4-(4-ΠΌΠ΅ΡΠΈΠ»-1,3-ΡΠΈΠ°Π·ΠΎΠ»-5-ΠΈΠ»)-4,6,7,8-ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½-2,5(1Π,3Π)-Π΄ΠΈΠΎΠ½ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½ΠΎΠ²ΡΠΌ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΠΌ Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΎΠΌ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² TRPA1, ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ ΡΡΠ°ΡΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΡΠ΅Π΄ΡΡΠ²ΠΎΠΌ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΡ. ΠΠ»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π΅Π³ΠΎ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ, ΡΠΏΠΎΡΠΎΠ±Π½ΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° Π³ΠΎΡΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΄ΡΠΊΡΠ°. Π ΡΠ°ΠΊΠΈΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½Π°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ»ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° ΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π΄ΠΈΡΡΠ°ΠΊΡΠΈΠΎΠ½Π½ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΡΠΎΡΠΊΠΎΠ²Π°Ρ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠ°Ρ Π΄ΠΈΡΡΠ°ΠΊΡΠΈΡ Π±ΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° Π½Π° Π΄ΠΈΡΡΠ°ΠΊΡΠΎΠΌΠ΅ΡΡΠ΅ Bruker D8 Discover, ΠΎΠ±ΠΎΡΡΠ΄ΠΎΠ²Π°Π½Π½ΠΎΠΌ Π½ΠΈΠΊΠ΅Π»Π΅Π²ΡΠΌ ΡΠΈΠ»ΡΡΡΠΎΠΌ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½Π½ΠΎ-ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π΄Π΅ΡΠ΅ΠΊΡΠΎΡΠΎΠΌ. Π Π°ΡΡΠ΅ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ½ΡΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΠΉ DIFFRAC.SUITE EVA ΠΈ TOPAS 4.2. Π‘ΡΠ΅ΠΌΠΊΠ° ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»Π°ΡΡ Π² Π³Π΅ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΡΡΠ³Π³Π°-ΠΡΠ΅Π½ΡΠ°Π½ΠΎ, Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΠΎΡΡΠ°ΠΆΠ΅Π½ΠΈΡ. ΠΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»Π»Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ Π±ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ ΠΏΡΠΈ ΠΏΠ΅ΡΠ΅ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΠΈ ΠΈΡ ΡΠΌΠ΅ΡΠ΅ΠΉ. Π Π΅Π½ΡΠ³Π΅Π½ΠΎΡΡΡΡΠΊΡΡΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π±ΡΠ» Π²ΡΠΏΠΎΠ»Π½Π΅Π½ Π½Π° ΠΌΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΌ Π΄ΠΈΡΡΠ°ΠΊΡΠΎΠΌΠ΅ΡΡΠ΅ Xcalibur-3. ΠΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»ΡΠ½ΡΠ΅ ΡΡΡΡΠΊΡΡΡΡ ΡΠ°ΡΡΠΈΡΡΠΎΠ²Π°Π½Ρ ΠΏΡΡΠΌΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ SHELXTL. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎΡΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΉ Π΄ΠΈΡΡΠ°ΠΊΡΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°Π· Π² Π½Π°ΡΠΈΠ²Π½ΠΎΠΌ ΠΎΠ±ΡΠ°Π·ΡΠ΅ ΠΠ€Π‘, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΎΠ½ΠΈ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°ΡΡ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΡ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ Π±ΡΠ»ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠΎΠ½ΠΎΠΊΡΠΈΡΡΠ°Π»Π»ΠΎΠ², ΠΏΡΠΈΠ³ΠΎΠ΄Π½ΡΡ Π΄Π»Ρ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΡΡΡΡΠΊΡΡΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΡΠ΅Π½ΠΊΠ° ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² Π½Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π»Π° ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΎΠ². ΠΡΠ»ΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΈΠ· ΡΡΠ°Π½ΠΎΠ»Π° ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΠ·ΡΠ΅ΡΡΡ ΡΠΎΠΌΠ±ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ I, Π° ΠΈΠ· ΠΌΠ΅ΡΠ°Π½ΠΎΠ»Π°, ΠΈΠ·ΠΎΠΏΡΠΎΠΏΠ°Π½ΠΎΠ»Π°, Π°ΡΠ΅ΡΠΎΠ½Π°, ΡΠΌΠ΅ΡΠ΅ΠΉ Π°ΡΠ΅ΡΠΎΠ½/Π°ΡΠ΅ΡΠΎΠ½ΠΈΡΡΠΈΠ» ΠΈΠ»ΠΈ Π’ΠΠ€/Π°ΡΠ΅ΡΠΎΠ½ΠΈΡΡΠΈΠ» - ΡΡΠΈΠΊΠ»ΠΈΠ½Π½Π°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ II. ΠΡΠ»ΠΈ ΠΎΠΏΠΈΡΠ°Π½Ρ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΌ ΡΡΡΠΎΠ΅Π½ΠΈΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΎΠ² ΠΈ ΠΈΡ ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠΈ Π² ΠΊΡΠΈΡΡΠ°Π»Π»Π°Ρ . ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΈ ΠΎΡ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΡ ΠΠ€Π‘ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΎΡΠ΅Π½Π΅Π½Ρ Ρ ΡΠ΅Π»ΡΡ Π²ΡΠ±ΠΎΡΠ° ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΎΠΉ ΠΊΡΠΈΡΡΠ°Π»Π»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π΄Π»Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ Π½Π° Π΅Π΅...
- 1 January 2022
- Published byΒ Russian Vrach, Publishing House Ltd.Β inΒ Farmaciya (Pharmacy)
- Vol.Β 71 Β (3) , 42-47
The study of technological properties and biopharmaceutical solubility of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity
ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΏΡΠΈΠ½ΡΠΈΠΏΠ°ΠΌΠΈ, Π·Π°Π»ΠΎΠΆΠ΅Π½Π½ΡΠΌΠΈ Π² ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²Π΅ ICH Q8, Π΄Π»Ρ ΠΏΠΎΡΠ΅ΡΠΈΠΉΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π΄ΠΎΠ»ΠΆΠ½Ρ Π±ΡΡΡ ΠΈΠ·ΡΡΠ΅Π½Ρ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ Π΅Π³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ², ΡΠΏΠΎΡΠΎΠ±Π½ΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ Π³ΠΎΡΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΄ΡΠΊΡΠ°. Π ΠΏΠΎΠ΄ΠΎΠ±Π½ΡΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ ΠΎΡΠ½ΠΎΡΡΡΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ. Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ: ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² ΠΈ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° - Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠ° TRPA1 Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ (ΠΠ€) Π½Π° Π΅Π³ΠΎ ΠΎΡΠ½ΠΎΠ²Π΅. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ΡΠΏΡΡΠ΅ΡΡΡ ΠΈ ΡΠ³ΠΎΠ» Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠΊΠΎΡΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ΅ΡΡΠ΅ΡΠ° ΡΡΠΏΡΡΠ΅ΡΡΠΈ Erweka GTL. ΠΠ°ΡΡΠΏΠ½ΠΎΠΉ ΠΎΠ±ΡΠ΅ΠΌ Π΄ΠΎ ΠΈ ΠΏΠΎΡΠ»Π΅ ΡΠΏΠ»ΠΎΡΠ½Π΅Π½ΠΈΡ ΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ΅ΡΡΠ΅ΡΠ° Π½Π°ΡΡΠΏΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ETD-1020. Π Π°Π²Π½ΠΎΠ²Π΅ΡΠ½ΡΡ Π±ΠΈΠΎ-ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π½Π° ΡΠ΅ΡΡΠ΅ΡΠ΅ Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ Β«Π Π°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΠ΅Β» DT 626/1000 HH. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠ΅ΡΠ΅ΡΠ΅Π΄ΡΠ΅Π³ΠΎ Π² ΡΠ°ΡΡΠ²ΠΎΡ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π½Π° Π£Π€-ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΎΡΠΎΠΌΠ΅ΡΡΠ΅ Agilent 8453. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΡΠΏΡΡΠ΅ΡΡΡ Π΄Π»Ρ Π²ΠΎΡΠΎΠ½ΠΊΠΈ Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ 25 ΠΌΠΌ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 18,68Β±1,15 Π³/Ρ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΠΉ ΡΠ³ΠΎΠ» Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠΊΠΎΡΠ° - 46,37Β±2,04Β°, ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½Ρ ΠΏΡΠ΅ΡΡΡΠ΅ΠΌΠΎΡΡΠΈ ΠΈ Π₯Π°ΡΡΠ½Π΅ΡΠ° - 31,83Β±1,33%, ΠΈ 1,47Β±0,09 ΠΠ΄ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠΈ ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΠΌ Π·Π½Π°ΡΠ΅Π½ΠΈΠΈ pH ΡΠ°ΡΡΡΠΈΡΠ°Π½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π΄ΠΎΠ·Π° Π²Π΅ΡΠ΅ΡΡΠ²Π° Π½Π΅ ΡΠ°ΡΡΠ²ΠΎΡΡΠ»Π°ΡΡ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ Π² 250 ΠΌΠ» ΡΡΠ΅Π΄Ρ. ΠΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΈ pH 1,2, 4,5 ΠΈ 6,8 ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 26,64Β±1,36; 2,72Β±0,15 ΠΈ 3,8Β±0,21 ΠΌΠΊΠ³/ΠΌΠ» ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π½Π½ΡΠ΅ ΠΎ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ²Π°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΠ΄Π΅Π»Π°ΡΡ Π²ΡΠ²ΠΎΠ΄ ΠΎ Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° Π³ΡΠ°Π½ΡΠ»ΡΡΠΈΠΈ ΠΈΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ Π²Π΅ΡΠ΅ΡΡΠ² Π΄Π»Ρ ΠΏΡΡΠΌΠΎΠ³ΠΎ ΠΏΡΠ΅ΡΡΠΎΠ²Π°Π½ΠΈΡ, Π° ΠΏΡΠΎΡΠΈΠ»Ρ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΡΠ½Π΅ΡΡΠΈ Π΅Π³ΠΎ ΠΊΠΎ II ΠΈΠ»ΠΈ IV ΠΊΠ»Π°ΡΡΡ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ΅ΠΌ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΠ€ Π΄ΠΎΠ»ΠΆΠ½Π° Π±ΡΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π° Π½Π° ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΈΠ»ΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΈ ΠΏΡΠΎΠ½ΠΈΡΠ°Π΅ΠΌΠΎΡΡΠΈ...
- 1 January 2022
- Published byΒ Russian Vrach, Publishing House Ltd.Β inΒ Farmaciya (Pharmacy)
- Vol.Β 71 Β (3) , 42-47
The study of technological properties and biopharmaceutical solubility of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity
ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΏΡΠΈΠ½ΡΠΈΠΏΠ°ΠΌΠΈ, Π·Π°Π»ΠΎΠΆΠ΅Π½Π½ΡΠΌΠΈ Π² ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²Π΅ ICH Q8, Π΄Π»Ρ ΠΏΠΎΡΠ΅ΡΠΈΠΉΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π΄ΠΎΠ»ΠΆΠ½Ρ Π±ΡΡΡ ΠΈΠ·ΡΡΠ΅Π½Ρ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ Π΅Π³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ², ΡΠΏΠΎΡΠΎΠ±Π½ΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ Π³ΠΎΡΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΄ΡΠΊΡΠ°. Π ΠΏΠΎΠ΄ΠΎΠ±Π½ΡΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ ΠΎΡΠ½ΠΎΡΡΡΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ. Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ: ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² ΠΈ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΈΠ»ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡ ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° - Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠ° TRPA1 Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ (ΠΠ€) Π½Π° Π΅Π³ΠΎ ΠΎΡΠ½ΠΎΠ²Π΅. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ΡΠΏΡΡΠ΅ΡΡΡ ΠΈ ΡΠ³ΠΎΠ» Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠΊΠΎΡΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ΅ΡΡΠ΅ΡΠ° ΡΡΠΏΡΡΠ΅ΡΡΠΈ Erweka GTL. ΠΠ°ΡΡΠΏΠ½ΠΎΠΉ ΠΎΠ±ΡΠ΅ΠΌ Π΄ΠΎ ΠΈ ΠΏΠΎΡΠ»Π΅ ΡΠΏΠ»ΠΎΡΠ½Π΅Π½ΠΈΡ ΡΡΡΠ°Π½Π°Π²Π»ΠΈΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ΅ΡΡΠ΅ΡΠ° Π½Π°ΡΡΠΏΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ETD-1020. Π Π°Π²Π½ΠΎΠ²Π΅ΡΠ½ΡΡ Π±ΠΈΠΎ-ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π½Π° ΡΠ΅ΡΡΠ΅ΡΠ΅ Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ Β«Π Π°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΠ΅Β» DT 626/1000 HH. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠ΅ΡΠ΅ΡΠ΅Π΄ΡΠ΅Π³ΠΎ Π² ΡΠ°ΡΡΠ²ΠΎΡ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π½Π° Π£Π€-ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΎΡΠΎΠΌΠ΅ΡΡΠ΅ Agilent 8453. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΡΠΏΡΡΠ΅ΡΡΡ Π΄Π»Ρ Π²ΠΎΡΠΎΠ½ΠΊΠΈ Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ 25 ΠΌΠΌ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 18,68Β±1,15 Π³/Ρ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΠΉ ΡΠ³ΠΎΠ» Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠΊΠΎΡΠ° - 46,37Β±2,04Β°, ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½Ρ ΠΏΡΠ΅ΡΡΡΠ΅ΠΌΠΎΡΡΠΈ ΠΈ Π₯Π°ΡΡΠ½Π΅ΡΠ° - 31,83Β±1,33%, ΠΈ 1,47Β±0,09 ΠΠ΄ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠΈ ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΠΌ Π·Π½Π°ΡΠ΅Π½ΠΈΠΈ pH ΡΠ°ΡΡΡΠΈΡΠ°Π½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π΄ΠΎΠ·Π° Π²Π΅ΡΠ΅ΡΡΠ²Π° Π½Π΅ ΡΠ°ΡΡΠ²ΠΎΡΡΠ»Π°ΡΡ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ Π² 250 ΠΌΠ» ΡΡΠ΅Π΄Ρ. ΠΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΈ pH 1,2, 4,5 ΠΈ 6,8 ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 26,64Β±1,36; 2,72Β±0,15 ΠΈ 3,8Β±0,21 ΠΌΠΊΠ³/ΠΌΠ» ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π½Π½ΡΠ΅ ΠΎ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ²Π°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΠ΄Π΅Π»Π°ΡΡ Π²ΡΠ²ΠΎΠ΄ ΠΎ Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° Π³ΡΠ°Π½ΡΠ»ΡΡΠΈΠΈ ΠΈΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ Π²Π΅ΡΠ΅ΡΡΠ² Π΄Π»Ρ ΠΏΡΡΠΌΠΎΠ³ΠΎ ΠΏΡΠ΅ΡΡΠΎΠ²Π°Π½ΠΈΡ, Π° ΠΏΡΠΎΡΠΈΠ»Ρ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΡΠ½Π΅ΡΡΠΈ Π΅Π³ΠΎ ΠΊΠΎ II ΠΈΠ»ΠΈ IV ΠΊΠ»Π°ΡΡΡ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ΅ΠΌ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΠ€ Π΄ΠΎΠ»ΠΆΠ½Π° Π±ΡΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π° Π½Π° ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΈΠ»ΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΈ ΠΏΡΠΎΠ½ΠΈΡΠ°Π΅ΠΌΠΎΡΡΠΈ...